BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

675 related articles for article (PubMed ID: 33941107)

  • 1. COXIBs and 2,5-dimethylcelecoxib counteract the hyperactivated Wnt/β-catenin pathway and COX-2/PGE2/EP4 signaling in glioblastoma cells.
    Majchrzak-Celińska A; Misiorek JO; Kruhlenia N; Przybyl L; Kleszcz R; Rolle K; Krajka-Kuźniak V
    BMC Cancer; 2021 May; 21(1):493. PubMed ID: 33941107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Up-Regulation of Cyclooxygenase-2 (COX-2) Expression by Temozolomide (TMZ) in Human Glioblastoma (GBM) Cell Lines.
    Lombardi F; Augello FR; Artone S; Gugu MK; Cifone MG; Cinque B; Palumbo P
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological inhibition of serine synthesis enhances temozolomide efficacy by decreasing O
    Jin L; Kiang KM; Cheng SY; Leung GK
    Lab Invest; 2022 Feb; 102(2):194-203. PubMed ID: 34625658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-126-3p sensitizes glioblastoma cells to temozolomide by inactivating Wnt/β-catenin signaling via targeting SOX2.
    Luo W; Yan D; Song Z; Zhu X; Liu X; Li X; Zhao S
    Life Sci; 2019 Jun; 226():98-106. PubMed ID: 30980849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The anti-proliferative potency of celecoxib is not a class effect of coxibs.
    Schiffmann S; Maier TJ; Wobst I; Janssen A; Corban-Wilhelm H; Angioni C; Geisslinger G; Grösch S
    Biochem Pharmacol; 2008 Jul; 76(2):179-87. PubMed ID: 18547544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma.
    Guo G; Sun Y; Hong R; Xiong J; Lu Y; Liu Y; Lu J; Zhang Z; Guo C; Nan Y; Huang Q
    Clin Transl Oncol; 2020 Aug; 22(8):1252-1262. PubMed ID: 31865606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2,5-Dimethyl Celecoxib Inhibits Proliferation and Cell Cycle and Induces Apoptosis in Glioblastoma by Suppressing CIP2A/PP2A/Akt Signaling Axis.
    Gao D; Nyalali AMK; Hou Y; Xu Y; Zhou J; Zhao W; Huang B; Li F
    J Mol Neurosci; 2021 Aug; 71(8):1703-1713. PubMed ID: 33400072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PARP‑1 inhibition sensitizes temozolomide‑treated glioblastoma cell lines and decreases drug resistance independent of MGMT activity and PTEN proficiency.
    Montaldi AP; Lima SCG; Godoy PRDV; Xavier DJ; Sakamoto-Hojo ET
    Oncol Rep; 2020 Nov; 44(5):2275-2287. PubMed ID: 32901889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
    Chen Z; Wei X; Shen L; Zhu H; Zheng X
    Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Celecoxib and 2,5-dimethylcelecoxib inhibit intestinal cancer growth by suppressing the Wnt/β-catenin signaling pathway.
    Egashira I; Takahashi-Yanaga F; Nishida R; Arioka M; Igawa K; Tomooka K; Nakatsu Y; Tsuzuki T; Nakabeppu Y; Kitazono T; Sasaguri T
    Cancer Sci; 2017 Jan; 108(1):108-115. PubMed ID: 27761963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NBM-BMX, an HDAC8 Inhibitor, Overcomes Temozolomide Resistance in Glioblastoma Multiforme by Downregulating the β-Catenin/c-Myc/SOX2 Pathway and Upregulating p53-Mediated MGMT Inhibition.
    Tsai CY; Ko HJ; Chiou SJ; Lai YL; Hou CC; Javaria T; Huang ZY; Cheng TS; Hsu TI; Chuang JY; Kwan AL; Chuang TH; Huang CF; Loh JK; Hong YR
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NMDA receptor signaling induces the chemoresistance of temozolomide via upregulation of MGMT expression in glioblastoma cells.
    Tsuji S; Nakamura S; Shoda K; Yamada T; Shimazawa M; Nakayama N; Iwama T; Hara H
    J Neurooncol; 2022 Nov; 160(2):375-388. PubMed ID: 36308592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quercetin induces MGMT
    Wang W; Yuan X; Mu J; Zou Y; Xu L; Chen J; Zhu X; Li B; Zeng Z; Wu X; Yin Z; Wang Q
    Phytomedicine; 2023 Sep; 118():154933. PubMed ID: 37451151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temozolomide Induces the Acquisition of Invasive Phenotype by O6-Methylguanine-DNA Methyltransferase (MGMT)
    Kochanowski P; Catapano J; Pudełek M; Wróbel T; Madeja Z; Ryszawy D; Czyż J
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33923767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.
    Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S
    Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sulforaphane enhances temozolomide-induced apoptosis because of down-regulation of miR-21 via Wnt/β-catenin signaling in glioblastoma.
    Lan F; Pan Q; Yu H; Yue X
    J Neurochem; 2015 Sep; 134(5):811-8. PubMed ID: 25991372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alterations in Cell Motility, Proliferation, and Metabolism in Novel Models of Acquired Temozolomide Resistant Glioblastoma.
    Tiek DM; Rone JD; Graham GT; Pannkuk EL; Haddad BR; Riggins RB
    Sci Rep; 2018 May; 8(1):7222. PubMed ID: 29740146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma.
    Stockhammer F; Misch M; Koch A; Czabanka M; Plotkin M; Blechschmidt C; Tuettenberg J; Vajkoczy P
    J Neurooncol; 2010 Dec; 100(3):407-15. PubMed ID: 20446016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance.
    Wickström M; Dyberg C; Milosevic J; Einvik C; Calero R; Sveinbjörnsson B; Sandén E; Darabi A; Siesjö P; Kool M; Kogner P; Baryawno N; Johnsen JI
    Nat Commun; 2015 Nov; 6():8904. PubMed ID: 26603103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. UBE2T Promotes Temozolomide Resistance of Glioblastoma Through Regulating the Wnt/β-Catenin Signaling Pathway.
    Wang Y; Gao G; Wei X; Zhang Y; Yu J
    Drug Des Devel Ther; 2023; 17():1357-1369. PubMed ID: 37181827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.